Pacific Edge's revenue climbs, US future still uncertain

Pacific Edge's revenue climbs, US future still uncertain
Very strong revenue growth, but profit still some distance away (Image: Pacific Edge)
Ella Somers
A boom in Pacific Edge’s Cxbladder test sales boosted the firm’s operating revenue soar by 71%, with a helping hand from favourable exchange rates.Chief executive Peter Meintjes said the 2023 financial year had been a year of “enormous change and achievement” for the cancer diagnostic company.“Pacific Edge is geared for growth,” he told the NZX.Operating revenue for the twelve months to March 31 rose $19.6 million, up from $11.4m in the previous year while total revenue jumped 88% to $26.1m.The revenue climb...

More Markets

NZ sharemarket up 0.5% ahead of long weekend
Markets Market Close

NZ sharemarket up 0.5% ahead of long weekend

Pacific Edge's share price fell 7.32%.

Tom Raynel 24 Apr 2025
Pacific Edge suffers another setback in US
Markets

Pacific Edge suffers another setback in US

Shares in cancer diagnostics company Pacific Edge are down 2.44% to $0.120 after another setback in the US market.The US District Court for the Middle District of Pennsylvania has determined that it does not have jurisdiction to review a Local Coverage Determination (LCD) that co...

Staff reporters 24 Apr 2025
Listed retailers stand to gain from Trump tariffs:  Forsyth Barr
Retail

Listed retailers stand to gain from Trump tariffs: Forsyth Barr

Forsyth Barr lifted its KMD Brands target price by 10.4% after Trump tariff walkbacks.

Gregor Thompson 24 Apr 2025
NZ sharemarket rises as Trump backs down
Markets Market Close

NZ sharemarket rises as Trump backs down

The S&P/NZX 50 Index closed up 1.01% or 119.78 points.

Tom Raynel 23 Apr 2025